Healthcare provider profile · identity verified

Leslie Harris, MD

Internal Medicine · MONTGOMERY, AL · NPI 1891755971

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	661	253
Amlodipine Besylate	Amlodipine Besylate	627	230
Losartan Potassium	Losartan Potassium	461	169
Pantoprazole Sodium	Pantoprazole Sodium	329	119
Carvedilol	Carvedilol	256	104
Albuterol Sulfate Hfa	Albuterol Sulfate	247	79
Ozempic	Semaglutide	213	47
Fluticasone Propionate	Fluticasone Propionate	208	94
Metformin Hcl	Metformin Hcl	195	70
Gabapentin	Gabapentin	194	82
Levothyroxine Sodium	Levothyroxine Sodium	160	60
Metoprolol Succinate	Metoprolol Succinate	158	60
Spironolactone	Spironolactone	154	50
Hydrochlorothiazide	Hydrochlorothiazide	152	51
Chlorthalidone	Chlorthalidone	150	56
Farxiga	Dapagliflozin Propanediol	145	48
Rosuvastatin Calcium	Rosuvastatin Calcium	141	51
Eliquis	Apixaban	131	34
Furosemide	Furosemide	131	57
Duloxetine Hcl	Duloxetine Hcl	120	39
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	120	34
Lisinopril	Lisinopril	120	48
Omeprazole	Omeprazole	118	46
Hydralazine Hcl	Hydralazine Hcl	117	42
Potassium Chloride	Potassium Chloride	114	41
Diclofenac Sodium	Diclofenac Sodium	111	42
Jardiance	Empagliflozin	101	30
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	98	31
Tamsulosin Hcl	Tamsulosin Hcl	97	31
Montelukast Sodium	Montelukast Sodium	93	30
Allopurinol	Allopurinol	92	35
Prednisone	Prednisone	84	69
Pravastatin Sodium	Pravastatin Sodium	83	31
Famotidine	Famotidine	78	33
Metoprolol Tartrate	Metoprolol Tartrate	74	25
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	73	30
Ezetimibe	Ezetimibe	71	25
Escitalopram Oxalate	Escitalopram Oxalate	64	22
Xarelto	Rivaroxaban	61	13
Amitriptyline Hcl	Amitriptyline Hcl	60	19
Clopidogrel	Clopidogrel Bisulfate	55	19
Trazodone Hcl	Trazodone Hcl	54	24
Mounjaro	Tirzepatide	53	13
Metformin Hcl Er	Metformin Hcl	52	16
Nifedipine Er	Nifedipine	52	17
Olmesartan Medoxomil	Olmesartan Medoxomil	52	18
Trulicity	Dulaglutide	51	11
Sertraline Hcl	Sertraline Hcl	50	20
Ramipril	Ramipril	47	16
Symbicort	Budesonide/Formoterol Fumarate	46	15
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	45	16
Tizanidine Hcl	Tizanidine Hcl	44	13
Buspirone Hcl	Buspirone Hcl	40	13
Meloxicam	Meloxicam	39	14
Januvia	Sitagliptin Phosphate	37	13
Pregabalin	Pregabalin	36	14
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	35	16
Novolog Flexpen	Insulin Aspart	35	12
Donepezil Hcl	Donepezil Hcl	33	14
Dicyclomine Hcl	Dicyclomine Hcl	31	suppressed
Entresto	Sacubitril/Valsartan	31	13
Esomeprazole Magnesium	Esomeprazole Magnesium	31	suppressed
Simvastatin	Simvastatin	31	13
Lantus	Insulin Glargine,hum.Rec.Anlog	29	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	28	suppressed
Clonidine Hcl	Clonidine Hcl	28	suppressed
Colchicine	Colchicine	28	12
Spiriva Respimat	Tiotropium Bromide	28	suppressed
Ibuprofen	Ibuprofen	26	14
Promethazine Hcl	Promethazine Hcl	26	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	26	14
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	25	22
Linzess	Linaclotide	25	12
Zolpidem Tartrate	Zolpidem Tartrate	25	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	24	suppressed
Clonazepam	Clonazepam	23	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	23	suppressed
Mirtazapine	Mirtazapine	23	12
Ondansetron Hcl	Ondansetron Hcl	23	12
Brilinta	Ticagrelor	22	suppressed
Celecoxib	Celecoxib	22	suppressed
Citalopram Hbr	Citalopram Hydrobromide	22	suppressed
Glipizide Er	Glipizide	22	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	22	11
Ibandronate Sodium	Ibandronate Sodium	22	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	22	suppressed
Meclizine Hcl	Meclizine Hcl	22	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Baclofen	Baclofen	21	suppressed
Breo Ellipta	Fluticasone/Vilanterol	21	13
Levetiracetam	Levetiracetam	21	11
Tramadol Hcl	Tramadol Hcl	21	suppressed
Humalog Kwikpen U-100	Insulin Lispro	20	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	19	suppressed
Alendronate Sodium	Alendronate Sodium	18	suppressed
Azithromycin	Azithromycin	18	17
Clonidine	Clonidine	18	suppressed
Lansoprazole	Lansoprazole	18	suppressed
Amiodarone Hcl	Amiodarone Hcl	17	suppressed
Bumetanide	Bumetanide	17	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	17	13
Methocarbamol	Methocarbamol	17	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	17	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	17	suppressed
Fluconazole	Fluconazole	16	11
Warfarin Sodium	Warfarin Sodium	16	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	15	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	15	suppressed
Nitroglycerin	Nitroglycerin	15	suppressed
Lovastatin	Lovastatin	14	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Tresiba Flextouch U-200	Insulin Degludec	14	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	14	suppressed
Acetazolamide	Acetazolamide	13	suppressed
Clotrimazole	Clotrimazole	13	suppressed
Finasteride	Finasteride	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Memantine Hcl	Memantine Hcl	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Ranolazine Er	Ranolazine	12	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	12	suppressed
Glipizide	Glipizide	11	suppressed
Nystatin	Nystatin	11	suppressed
Tradjenta	Linagliptin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error